Lexicon Pharmaceuticals Completes HCM Study Enrollment Ahead of Schedule — Lexicon Pharmaceuticals, Inc.

Event summary

Completed enrollment in Phase 3 SONATA-HCM study ahead of schedule with 500 patients.
NDA resubmission for ZYNQUISTA® in type 1 diabetes expected in Q4 2026.
Phase 1 clinical development of LX9851 by Novo Nordisk ongoing, with completion expected in Q1 2027.
Reported $31.8 million net loss for Q2 2026, down from a profit of $3.3 million in Q2 2025.

The big picture

Lexicon Pharmaceuticals is advancing its cardiometabolic pipeline with key milestones in hypertrophic cardiomyopathy (HCM) and type 1 diabetes. The completion of the SONATA-HCM study enrollment ahead of schedule reflects strong clinical interest, while the NDA resubmission for ZYNQUISTA® could expand treatment options for type 1 diabetes patients. The company's financial performance, however, shows a significant decline in revenue and an increase in net loss, highlighting the challenges of balancing growth with financial stability.

What we're watching

Regulatory Approval: Whether the NDA resubmission for ZYNQUISTA® will be approved by the FDA in Q4 2026.
Clinical Trial Results: The impact of the Phase 3 SONATA-HCM study results expected in Q1 2027 on Lexicon's strategic positioning.
Financial Stability: How Lexicon will manage its increased R&D expenses and net loss while advancing its clinical programs.